Covid vaccine maker Moderna, Inc. (MRNA) reported Thursday that its first-quarter net income plunged to $79 million from last year's $3.66 billion. Earnings per share were $0.19, down from $8.58 a year ago.
On average, 14 analysts polled by Thomson Reuters expected loss of $1.77 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenue for the first quarter was $1.86 billion, sharply lower than prior year's $6.1 billion. Analysts expected revenues of $1.18 billion for the quarter.
The drop in revenues mainly reflected a decrease in sales of the company's COVID-19 vaccines. Product sales were $1.8 billion, a decrease of 69 percent, primarily driven by lower sales volume.
Further, Moderna reiterated its expectation of 2023 minimum sales of around $5.0 billion from previously announced COVID-19 vaccine Advanced Purchase Agreements.
The company estimates the U.S. annual COVID-19 market to be 100 million doses. The firm is in active supply discussions for new COVID-19 vaccine orders for fall of 2023 in the U.S., Japan, and the E.U.
The company projects second-quarter sales between $0.2 billion and $0.3 billion, and continues to expect total product sales in the first half of 2023 of around $2.0 billion.
In pre-market activity on Nasdaq, Moderna shares were trading at $132.85, up 2.08 percent.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.